FDA Speeds Up Psychedelic Drug Trials for Mental Health

FDA Accelerates Psychedelic Drug Trials for Mental Health Battles The FDA has announced a significant push to expedite psychedelic drug trials for treatment-resistant depression, PTSD, and substance use disorders. This move comes after President Trumps executive order, which encourages federal health agencies to fast-track cutting-edge treatments. The FDA is now offering national priority vouchers to companies testing psilocybin for depression and methylone for PTSD. This development is hailed as a game-changer, prioritizing therapies with early promise in mental health care. Additionally, the agency has cleared the first-ever U.S. trial for noribogaine hydrochloride, a compound from ibogaine, aimed at alcohol use disorder. These steps mark a significant shift in the approach to psychedelics for healing, with research rolling and data under tight watch. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/f752aa4dab98b0f4